AMBIENTUM BIOETHICA BIOLOGIA CHEMIA DIGITALIA DRAMATICA EDUCATIO ARTIS GYMNAST. ENGINEERING EPHEMERIDES EUROPAEA GEOGRAPHIA GEOLOGIA HISTORIA HISTORIA ARTIUM INFORMATICA IURISPRUDENTIA MATHEMATICA MUSICA NEGOTIA OECONOMICA PHILOLOGIA PHILOSOPHIA PHYSICA POLITICA PSYCHOLOGIA-PAEDAGOGIA SOCIOLOGIA THEOLOGIA CATHOLICA THEOLOGIA CATHOLICA LATIN THEOLOGIA GR.-CATH. VARAD THEOLOGIA ORTHODOXA THEOLOGIA REF. TRANSYLVAN
Rezumat articol ediţie STUDIA UNIVERSITATIS BABEŞ-BOLYAI
În partea de jos este prezentat rezumatul articolului selectat. Pentru revenire la cuprinsul ediţiei din care face parte acest articol, se accesează linkul din titlu. Pentru vizualizarea tuturor articolelor din arhivă la care este autor/coautor unul din autorii de mai jos, se accesează linkul din numele autorului.
Autori: ALEXANDRA RUSU, LAURA PĂTRAȘ, MANUELA BANCIU.
5-Fluorouracil (5-FU) is an antimetabolite drug used to treat various cancer types, especially colon cancer. Its mechanism of action includes the inhibition of the biosynthetic processes in proliferating cells by inhibiting the normal function of DNA and RNA. 5-FU has a short half-life since 80% of the administered drug is catabolized in the liver. Moreover, the therapies based on the 5-FU administration are accompanied by severe side effects such as immunosuppression, cardiotoxicity, and neurotoxicity. Therefore, the use of the nanoparticle-encapsulated 5-FU can target efficiently colorectal cancer, could reduce the major drawbacks of conventional administration of 5-FU and also increase the drug lifetime and its tumour accumulation, and finally 5-FU therapeutic index will be enhanced. To this end, this article aims to review the recent research regarding nanoparticles encapsulating 5-FU for colorectal cancer targeted therapy.
Keywords: 5-fluorouracil, colorectal cancer, nanoparticles
